Urinary bladder neoplasm is one of the most common cancers worldwide. Cancer stem cells (CSCs) have been proven to be an important cause of cancer progression and poor prognosis. In the present study, we established bladder CSCs and identified the crucial differentially expressed genes (DEGs) between these cells and parental bladder cancer cells. Analyses of bioinformatics data and clinical samples from local hospitals showed that stearoyl CoA desaturase-1 (SCD) was the key factor among the DEGs. A significant correlation between SCD gene expression and poor prognosis among patients with bladder cancer was observed in our data. Loss-offunction experiments further revealed that the SCD inhibitor A939572 and SCD gene interference reduced cell proliferation and invasion. The above data suggest that SCD may serve as a novel marker for the prediction of tumour progression and poor prognosis in patients with bladder cancer.
cancer (NMIBC) could suffer tumour recurrence, and approximately 10%-15% of these patients progress to muscle-invasive bladder cancer (MIBC). 4 Therefore, accurate prediction of tumour recurrence and progression is important for determining the appropriate therapy and disease follow-up.
Cancer cells are heterogeneous and are assumed to include cancer stem cells (CSCs). The experimental evidence of CSCs was first described in haematology. 5, 6 According to the consensus definition of CSCs, 7 these cells have the capacity for self-renewal and the ability to generate the heterogeneous lineages of cancer cells that compose the tumour.
The remarkable pathological differences between NMIBC and MIBC lead to substantial differences in disease progression and outcome. Compared with NMIBC, MIBC consists of a wider variety of cancer cells that range from differentiated to undifferentiated.
Urothelial stem cells localize in the basal cell layer and generate all different types of urothelial cells. 8 When the urothelium is partially injured, urothelial stem cells are capable of regeneration and compensation for the damaged tissue. However, the regenerative trait of stem cells is strictly co-ordinated in the normal urothelial lineage, thereby preventing tumour formation. Bladder CSCs (BCSCs) were first identified by sorting with markers of normal basal cells. 9 Many studies have reported new methods for identifying BCSCs, and the results progressively support the existence of BCSCs. 10 Nevertheless, the origin of BCSCs and their mechanism of differentiation are mostly undiscovered.
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In the present study, we suggested that BCSCs are responsible for the poor prognosis of patients with bladder cancer. Therefore, 
| MATERIALS AND METHODS

| Cell culture and reagents
The human bladder cancer cell lines 5637, T24, UMUC3 and J82
were cultured in RPMI-1640 medium, RT4 cells were cultured in
McCoy's 5A medium and TCCSUP cells were cultured in Dulbecco's modified Eagle's medium (DMEM). All culture media were supplemented with 10% foetal bovine serum. All cancer cell lines were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured under humidified air containing 5% CO 2 at 37°C. When the cells reached over 80% confluence, they were washed with 1× PBS and trypsinized at 37°C for a specified number of minutes for cell passage cultivation.
A939572 was purchased from MedChem Express. The catalog number is HY-50709.
| Isolation and propagation of BCSCs
Monolayers of 5637 and T24 BCSCs were dissociated in trypsin (0.25%)/EDTA, plated in ultralow attachment flasks (Corning) at a density of 10 000 cells/mL and grown in serum-free medium (DMEM/F12; 1:1 mixture) containing B27 (Invitrogen) and supplemented with recombinant epidermal growth factor (EGF) at 20 ng/ mL (Invitrogen) and recombinant bFGF at 10 ng/mL (Invitrogen).
Each generation of CSCs was cultured for 7-10 days and the sphere cells were subcultured using trypsin and resuspended in serum-free medium described above. The third generation spheres were used for identification of stemness and microarray analysis.
| Microarray analysis
Samples of total RNA from the parental 5637/T24 cell line and 5637/T24 sphere cells were analysed on an Affymetrix HTA 2.0
Array. The arrays were scanned by an Affymetrix GeneChip ® Scanner 3000 (Cat# 00-00213; Affymetrix, Santa Clara, CA, USA). Command Console Software (Affymetrix) was used with the default settings to control the scanner and summarize probe cell intensity data (CEL file generation). Then, the raw data were normalized by Expression Console.
| Data pre-processing and DEG screening
The probe-level data in CEL files were converted into an expression value matrix by GCBI online platform analysis at the following link: http://www.gcbi.com.cn. Robust Multichip Average, including the background-correction, normalization and summary features, was used to compute the expression value. Quality control of the gene expression data was performed using a gene-specific probe.
The median normalized unscaled standard error value of each chip was applied to evaluate the feasibility of the design and the reliability of the analysis results. We further assessed the change rule of every probe set in the experiment by computing the relative log expression (RLE). The unified standard criterion for every sample was as follows: (1-0.2) <median <(1 + 0.2) and (−0.25) <median {RLE} <(0.25). Chips that deviated far from this criterion were rejected.
To identify DEGs between the parental 5637/T24 bladder cancer cells and 5637/T24 CSCs, only probe signals with P-values <0.01, qvalues <0.05 and absolute values of fold change (FC) >3 were considered to be significantly differentially expressed.
| Bioinformatics analyses
To assess the survival curve and expression levels of SCD mRNA in the normal bladder vs bladder cancer, the ONCOMINE database (https://www.oncomine.org) and The Cancer Genome Atlas (TCGA)
were interrogated. TCGA platform analysis is available at the following link: http://gepia.cancer-pku.cn.
| Gene expression analysis by quantitative RT-PCR
Total RNA was isolated from whole bladder cancer samples or bladder cancer cells using TRIzol reagent, treated with DNase I, and then used for cDNA synthesis with PrimeScript RT Master Mix. Quantitative RT-PCR analyses were performed using LightCycler with SYBR Premix Ex Taq. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal reference.
| Immunohistochemistry
Paraffin-embedded tissue blocks were cut in a certain orientation at a thickness of 4 μm to obtain serial sections of the normal bladder tissue or bladder cancer. The slices were mounted on glass slides.
Immunostaining was performed using the avidin-biotin-peroxidase complex method (Ultrasensitive overnight. Biotinylated goat anti-mouse serum IgG was used as a secondary antibody. After washing, the sections were incubated with streptavidin-biotin conjugated to horseradish peroxidase, and the immunoreaction was visualized using diaminobenzidine as a chromogen. As a control, incubation without the primary antibody or with non-specific serum was also performed. Nuclear staining was carried out by treating the slides with hemalum for 2 minutes, followed by a 10-minute incubation in running water to induce the colour reaction. Finally, the stained slices were dehydrated and mounted.
| Western blotting
Whole-cell lysates were extracted by using radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitors. Protein fractions were separated by 10% SDS-PAGE (140 V). The resolved proteins were transferred (350 mA) to PVDF membranes (0.2 μm) using a mini-transblot apparatus (Bio-Rad). The membranes were blocked with 5% non-fat milk at room temperature for 2 hours, incubated with the primary antibody at 4°C overnight and then incubated for 45 minutes with the appropriate secondary antibody.
Proteins were finally detected with Luminata substrate. Quantification of the immunoblots was performed using ImageJ software. All optical density values from immunoblots were normalized to the density values acquired for GAPDH.
| Cell proliferation assay
The effect of A939572 on cell proliferation was assessed by counting viable cells using a colorimetric assay in the Cell Counting Kit-8. 
| Colony formation
Single cells were plated in a 6-well plate at a density of 1000 cells per well in suitable medium. The cloning efficiency was calculated by ImageJ software.
| Cell cycle analysis
Flow cytometry was performed with a FACSCalibur Flow Cytometer.
All pre-treated cells were harvested, washed twice with PBS and fixed with 5 mL of 70% ethanol at 4°C overnight. Then, the cells were washed twice in PBS and resuspended in 500 µL of PI/RNase
Staining Buffer Solution (BD Pharmingen) in the dark at room temperature. Finally, cell cycle images were collected and analysed by using BD CellQuest Pro software and ModFit LT software. 
| Cell invasion assays
Invasion assays were performed using BD 24-well Boyden chambers.
A total of 2 × 10 5 cells were added to the top insert, and 500 µL of 10% FBS-containing medium was added to the bottom chamber.
After 24 hours of incubation, the cells that invaded the lower surface of the membrane were fixed, stained with 0.4% crystal violet and counted.
| Cell migration assay
Cell migration abilities were measured in modified Boyden chambers 
| In vivo tumourigenesis analysis
Cancer stem cells and their parental cells were subcutaneously injected into 4-week-old female nude mice in different amounts
, 10 5 , 10 6 and 10 7 cells). Tumour growth was observed every 3-5 days. After 5-6 weeks of observation, the injected nude mice were killed, and the tumourigenic ability between two groups at different cell amounts was compared.
| Statistical analysis
Experimental data are presented as the mean ± SD from at least three independent experiments performed in triplicate; differences between groups were analysed by Student's t test. Differences between groups in clinical data were evaluated by Mann-Whitney test or Dunn's multiple comparisons test. Survival status was analysed by Kaplan-Meier/Logrank methods. Statistical analysis was performed using GraphPad Prism version 7.0 software.
| RESULTS
| DEGs between BCSCs and common bladder cancer cell lines
Using the human bladder cancer cell lines 5637 and T24, we isolated BCSCs by culturing 5637 or T24 cells in serum-free DMEM/F12
(1:1) containing B27, recombinant EGF at 20 ng/mL and recombinant bFGF at 10 ng/mL. We cultured each generation of CSCs for 7-10 days and the sphere cells were subcultured using trypsin and resuspended in serum-free medium, then we used the third-generation spheres for microarray analysis ( Figure 1A ). The total isolation and propagation time were about 30 days. Before using the CSCs for microarray assay, we examined the expression of several regula- Figure 1F ) and between the parental T24 cells and T24 CSCs (Figure 1G) . Furthermore, to identify DEGs that were present in both DEG datasets, as shown, we intersected up-regulated DEGs or down-regulated DEGs using GCBI at the following link: http://www. gcbi.com.cn. Thirteen up-regulated genes and four down-regulated genes were identified, as displayed in the chart ( Figure 1H ). The heatmap shows the relative expression of each gene ( Figure 1I ). PCR were also performed on six cultured bladder cancer cell lines, and a similar result was observed ( Figure 3G,H) . Taken together, these data suggest that SCD is highly expressed in bladder tumours and could be a reliable target for further investigations.
| Blockade of SCD activity inhibits the proliferation of bladder cancer cell lines
To examine whether the SCD gene could affect the cellular function of bladder cancer cells, we inhibited SCD activity using two SCDspecific siRNAs and the SCD-specific inhibitor A939572. Two cell lines, UMUC3, a highly malignant cell line, and RT4, a transitional papilloma cell line, were used to perform a proliferation assay. As shown in Figure 4A , the growth curve revealed that after treatment with 3.2 or 25.6 µg/mL A939572, the inhibition of SCD activity significantly decreased the growth of UMUC3 and RT4 cells compared to that of the DMSO (0.25%) control. The colony formation assay revealed similar results, and the concentrations used for SCD blockade were 1.6 and 3.2 µg/mL ( Figure 4B ). As we identified SCD as a target using a BCSC microarray screening assay, a sphere formation assay was then performed to confirm the influence of SCD during the course of CSC formation. After 2 weeks of treatment at a concentration of 1.6 µg/mL A939572, we observed that UMUC3 and RT4 cells notably lost their sphere formation ability ( Figure 4C ). To obtain stronger evidence, we constructed SCD-knockdown cell lines using two SCD-specific siRNAs combined with an inhibitor-treated group. We next performed an EdU assay to determine the effect of SCD on cell proliferation using flow cytometry. As shown in Fig 
| Inhibition of SCD blocks the migration and invasion of bladder cancer cell lines in vitro
2To further explore the effect of the SCD gene on cellular functions, in vitro cell invasion and migration assays were performed. We used two aggressive bladder cancer cell lines, T24 and UMUC3, for the test. As shown in Figure 5A ,B, when the inhibitor was added at a concentration of 3.2 µg/mL, the invasion and migration abilities of the T24 and UMUC3 cell lines were significantly decreased. E-cadherin and N-cadherin, the most common epithelial-mesenchymal transition markers, are considered to be markers of migration and invasion. The cells were pre-treated with A939572 at concentrations of 6.4 and 12.8 µg/mL. Compared to that in the DMSO (0.25%) group, N-cadherin expression was remarkably down-regulated in inhibitor-treated cell lines, whereas E-cadherin expression was up-regulated ( Figure 5E ).
In summary, SCD inhibition was capable of decreasing the migration and invasion abilities of bladder cancer cell lines in vitro.
| The combination of an SCD inhibitor and pirarubicin does not enhance cancer apoptosis in vitro
Many studies reported that pharmacologic or genetic interference with SCD remarkably accelerated the process of cellular apoptosis in different types of cancer. Moreover, SCD inhibition could also A939572 at a concentration of 6.4 µg/mL did not improve the effect of the drug. In addition, A939572 treatment alone had no effect on cell survival ( Figure 5C ). The cell viability assay showed a similar trend. When combined with A939572 at concentrations of 3.2 and 25.6 µg/mL, the inhibitory effect of pirarubicin in UMUC3 or RT4 cells did not increase ( Figure 5D ). Interestingly, in CSCs, we observed a different result. As shown in Figure 5F , we treated 
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These experiments have, for the first time, found direct evidence that SCD is a key factor of tumour cell proliferation and survival. Subsequently, a series of researches showed that SCD inhibition has anti-proliferative and apoptosis effects in a variety of neoplasm cells. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] More evidence suggests that SCD modulates the replication rate of tumour cells by regulating certain factors in cell cycle progression.
Studies performed in lung cancer cells found that when SCD activity was inhibited, cancer cells were arrested in the G1 phase of the cell cycle. 41 The researchers demonstrated that the activity of relevant regulatory factors is dependent on the synthesis of MUFA. 41 One study showed that SCD, to some extent, controls cell cycle progression by regulating the expression levels of cyclin D1 and CDK6. 42 It was also reported that the inhibition of SCD in cancer cells could reduce the expression level of nuclear β-catenin, which can activate the expression of cyclin D1. 38 However, studies related to the changes of MUFA synthesis and the activation and progression of the cell cycle have yet to be elucidated.
Elegant studies clearly demonstrated that SCD activity is necessary for the replication and differentiation of human pluripotent stem cells. However, once the cells have completed the differentiation process, the desaturase activity is no longer the key for cell survival.
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F I G U R E 5 Inhibition of SCD blocks the migration and invasion of bladder cancer cell line; the combination of an SCD inhibitor and pirarubicin does not enhance cancer apoptosis. A, After treatment of A939572 (3.2 µg/mL), the invasion ability of T24 and UMUC3 cell lines were significantly decreased. B, After treatment of A939572 (3.2 µg/mL), the migration ability of T24 and UMUC3 cell lines were significantly decreased. C, Compared with treatment with DMSO, treatment with pirarubicin alone (100 ng/mL) significantly increased cell apoptosis. However, the combination of pirarubicin with A939572 (6.4 µg/mL) did not improve the effect of the drug. A939572 treatment alone had no effect on cell apoptosis. D, Combined with A939572 (3.2 and 25.6 µg/mL), the inhibitory effect of pirarubicin in UMUC3 (left) or RT4 (right) cells did not increase. E, Compared to the DMSO (0.25%) group, A939572 at concentrations of 6.4 and 12.8 µg/mL up-regulated E-cadherin expression and down-regulated N-cadherin expression. F, Compared to the control group, the outline of the spheres in the treatment group (A939572 alone at a concentration of 12.8 µg/mL for 48 h) was significantly smaller
Stearoyl CoA desaturase-1 has been shown to control many of the biological properties of cancer cells. Therefore, many studies reported that high levels of MUFA synthesis are essential for cancer development and growth. It is worth noting that when a glycolytic cell line MIA Paca-2, and a lipogenic cell line HPAC that expresses high levels of SCD and MUFAs, were treated with A37062, a SCD small molecule inhibitor, remarkable tumour growth suppression was observed only in the HPAC-derived xenografted tumour. 45 Although the antitumour effect of SCD suppression has been reported, milder therapeutic effect was observed in some cancers. In xenograft tumours deriving from MF-438 cells, treatment with the SCD inhibitor A939572 had no virtual antitumour impacts but suppressed tumour growth when carfilzomib was used. 37 In our study, the results suggested that treatment with A939572 did not cause apoptosis in parental bladder cancer cell lines. However, in CSCs, using an SCD inhibitor alone may reduce CSC proliferation and increase apoptosis.
However, the present study has several limitations. First, all confirmatory experiments were performed in vitro. In vivo data are necessary to support our findings, and in vivo experiments are our next step in confirming our results. Next, we were not able to explore the exact mechanism that underlies the biological function of SCD in bladder carcinoma. SCD regulates important survival and proliferation signalling pathways in tumour cells. The levels of SCD activity affect the carcinogenic phenotype by modulating critical oncogenic signalling pathways, especially AMPK, PI3K-Akt, Wnt, mTOR and NF-kB pathways. [46] [47] [48] [49] [50] To explore these mechanisms more fully, lipid metabolomic analysis and transcriptome analysis are necessary. Finally, the results of the present study may be a chance finding due to the limited sample size and the lack of additional validation. Therefore, additional large-scale and independent studies are essential.
